Toxicity Attributed to Genetic Polymorphisms in Testicular Germ Cell Tumor Survivors
NCT ID: NCT02303015
Last Updated: 2023-11-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
430 participants
OBSERVATIONAL
2014-08-31
2023-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Cause of Familial Testicular Cancer
NCT00034424
Germ Cell Tumor and Testicular Tumor DNA Registry
NCT02099734
MicroRNA as Markers in Testicular Cancer
NCT04914026
Identification of Predictive Markers for Testis Cancer in a Population of Men With High Risk
NCT00820287
A Case-Control Study of Testicular Germ Cell Tumors Among U.S. Military Servicemen
NCT00341588
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Danish germ cell cancer patients
Danish patients with germ cell cancer diagnosed from 1984 to 2007.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosed with germ cell cancer from 1984 to 2007
* Treated initially at a Danish hospital
* Treated with standard treatment regimens.
Exclusion Criteria
15 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Rigshospitalet, Denmark
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Gedske Daugaard
Professor M.D. DMSc
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Gedske Daugaard, MD DMSc
Role: PRINCIPAL_INVESTIGATOR
Rigshospitalet, Denmark
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Dept. of Oncology, Rigshospitalet
Copenhagen, , Denmark
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DaTeCa01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.